Autopsy report · NCT01312389

A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

“Did not meet criteria laid out in Phase 1 to continue to Phase 2”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 1 year 4 months before it stopped.
• 3 participants enrolled.
• Results were posted on the registry 9 years 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Abramson Cancer Center at Penn Medicine

Sponsor type

University, hospital or other

Conditions

Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer

Interventions

OC-L/Montanide ISA 51 VG; Ampligen; Prevnar

Participants

3

Sites

1

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.